October 26, 2019
Impella RP use results in 72% patient survival and 88% native heart recovery
DETROIT–(BUSINESS WIRE)–Please replace the caption for release dated October 25, 2019 with the accompanying corrected caption.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 25, 2019
Alvogen sells Central and Eastern European business to Zentiva
Alvogen is selling its Central and Eastern European business to Zentiva, for an undisclosed amount, to focus on developing other areas, with the transaction to be closed in first quarter of 2020.
October 25, 2019
Vistin Pharma ends Q3 2019 with revenue up 31%, and goes to net gain vs loss in Q3 2018
Vistin Pharma posted net financial gain for the third quarter NOK 68.1 million (€6.68M), compared to a net loss of NOK 4.3 million in the same period last year, resulting with the net financial gain for the quarter primarily relates to an unrealised gain on oil derivatives of NOK 66.7 million.
October 25, 2019
Colorado BioScience Association welcomes new directors
Four life sciences leaders bring deep expertise to support CBSA members, as they join as new members of the Board…
October 25, 2019
Neopharma, Elevar Therapeutics form JV to sell anticancer drug Rivoceranib
Abu Dhabi-based pharmaceutical manufacturer Neopharma and US-based Elevar Therapeutics formed a 50-50 joint venture in UAE, to organize selling Rivoceranib, a targeted anticancer drug and conduct clinical trials for other pipeline candidates.
October 25, 2019
FDA Post Approval Study shows timely identification of right heart failure and early use of Impella RP leads to higher survival
FDA post approval study shows timely identification of right heart failure and early use Abiomed’s ImMpella RP leads to higher…
October 24, 2019
Spectrum Pharmaceuticals submits updated BLA to the USFDA for Rolontis
Spectrum Pharmaceuticals has submitted updated BLA to the USFDA, for Rolontis, based on two large pivotal randomized controlled studies that…
October 24, 2019
NOXXON without revenues H1 2019, net loss down to €1.9M, from €4.0M in H1 2018
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by…
October 24, 2019
Tarveda Therapeutics preclinical studies of treatment for certain lung cancer shows PEN-221 allows deep tumor penetration
Tarveda Therapeutics said in a PR Friday that PEN-221 miniature drug conjugate allow for deep tumor penetration, while limiting plasma…
October 24, 2019
Xyphos Biosciences, Gladstone Institutes show convertibleCAR cells and bispecific broadly neutralizing antibodies reduce latent HIV reservoir
Xyphos Biosciences, Gladstone Institutes show convertibleCAR cells and bispecific broadly neutralizing antibodies reduce latent HIV reservoir.